Apnimed acquires global rights to sulthiame
04/25/25, 12:29 PM
Location
cambridge
hamburgIndustry
manufacturing
pharmaceutical
biotechnology
health care
manufacturing
Apnimed, Inc. has acquired the exclusive global rights to develop and commercialize sulthiame, a differentiated carbonic anhydrase inhibitor, from Desitin Arzneimittel GmbH. This acquisition will enhance Apnimed's portfolio in treating obstructive sleep apnea (OSA) through its joint venture with Shionogi. Sulthiame has completed successful Phase 2 trials and is approved for use in non-sleep-related diseases outside the US.
Company Info
Location
39 john f. kennedy street, 4th flr.
Cambridge, Massachusetts, United States
Company info
Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.